Zhejiang AngLiKang Pharmaceutical CO.,LTD.

SZSE:002940.SZ

17.9 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q4
Revenue 270.881435.901407.993438.885343.692418.783424.507505.324359.329365.575338.209393.492353.157314.849318.88371.399310.32302.127305.801329.164319.028365.209382.793370.125271.263346.561267.099282.566
Cost of Revenue 187.951246.833245.86253.411208.397208.285230.416241.318146.091151.006132.134135.675154.50287.818109.764148.52261.85758.18248.81275.07465.05698.007137.183117.54568.875112.79379.13164.518
Gross Profit 82.931189.068162.133185.474135.295210.498194.091264.006213.239214.569206.076257.818198.654227.031209.116222.877248.463243.945256.989254.089253.972267.202245.61252.58202.388233.768187.967218.047
Gross Profit Ratio 0.3060.4340.3970.4230.3940.5030.4570.5220.5930.5870.6090.6550.5630.7210.6560.60.8010.8070.840.7720.7960.7320.6420.6820.7460.6750.7040.772
Reseach & Development Expenses 62.54747.71549.08644.82344.35133.43520.7646.1426.82424.92714.7316.13413.51511.5611.34515.08710.5657.7910.43520.0716.6974.8565.72422.97311.6316.8054.80120.328
General & Administrative Expenses 0-2.29121.027-11.17341.4817.97219.684-32.02131.1184.56913.628-7.68623.8643.0417.346-11.45312.2957.50714.852-2.58619.2857.46110.854-1.69214.4543.7217.016-1.678
Selling & Marketing Expenses 040.26148.26848.27551.30681.028112.411156.856138.233130.703133.286170.336137.598157.821144.055149.91172.794172.71195.476178.32190.752204.23191.902194.367156.354160.377135.654143.787
SG&A 54.68463.13969.29637.10292.78789132.095124.835169.351135.272146.915162.65161.461160.861161.401138.457185.089180.216210.328175.735210.037211.691202.755192.675170.808164.098142.67142.109
Other Expenses -62.0380.129-0.219-1.786-2.6960.051-14.63958.406-11.45315.5911.288-0.232-0.862-0.4380.008-0.5830.2-0.5540.001-0.082-0.26-0.286-0.7852.0210.5712.5590.9230.589
Operating Expenses 116.721110.725112.383112.759120.103137.943138.217229.382184.722175.79162.933205.254167.199183.133175.378168.351197.786192.799209.394214.962219.164229.944206.059238.89185.358184.158148.041182.703
Operating Income -33.79178.34353.24857.1716.00880.13858.36523.02131.70845.14948.68155.26631.02747.23840.6450.56551.34857.80651.96233.37337.7141.38942.63210.11518.64161.53840.94531.305
Operating Income Ratio -0.1250.180.1310.130.0470.1910.1370.0460.0880.1240.1440.140.0880.150.1270.1360.1650.1910.170.1010.1180.1130.1110.0270.0690.1780.1530.111
Total Other Income Expenses Net 4.1125.583-0.219-1.786-2.6960.051-0.0510.017-1.7690.141-0.002-0.232-1.292.9030.008-4.5440.8716.1064.368-5.8362.6413.8452.297-1.5542.18114.4871.943-3.451
Income Before Tax -29.67983.92553.02955.38413.31280.18958.31423.03729.93945.2948.67955.03430.16546.840.64849.98251.54857.25251.96333.29137.4541.10341.84712.13619.21264.09741.86831.894
Income Before Tax Ratio -0.110.1930.130.1260.0390.1910.1370.0460.0830.1240.1440.140.0850.1490.1270.1350.1660.1890.170.1010.1170.1130.1090.0330.0710.1850.1570.113
Income Tax Expense -12.2246.3365.61913.209-0.214.3496.7874.4912.7161.1496.6025.52514.2137.5154.0714.97.8358.8647.8446.1737.2127.7156.132-0.8082.7358.0255.6915.389
Net Income -18.16539.87928.21928.5795.56557.15847.0719.02129.17140.01839.08644.659.61432.79832.78339.49139.15643.27841.79421.86625.19731.633.6089.49614.70750.95333.54122.831
Net Income Ratio -0.0670.0910.0690.0650.0160.1360.1110.0380.0810.1090.1160.1130.0270.1040.1030.1060.1260.1430.1370.0660.0790.0870.0880.0260.0540.1470.1260.081
EPS -0.0910.20.140.140.0280.280.230.0940.310.420.290.470.10.340.160.440.210.480.220.240.130.350.180.140.10.760.240.34
EPS Diluted -0.0910.20.140.140.0280.280.230.0940.310.420.290.460.10.340.160.440.210.480.220.240.130.350.180.140.10.760.240.34
EBITDA -26.053101.46355.87874.57518.3882.67358.35328.78632.48751.10646.50762.44730.32346.83136.3256.52252.56555.94952.66234.0137.79642.15941.56617.10518.02353.13441.64234.998
EBITDA Ratio -0.0960.2330.1370.170.0530.1970.1370.0570.090.140.1380.1590.0860.1490.1140.1520.1690.1850.1720.1030.1180.1150.1090.0460.0660.1530.1560.124